Related Experiment Video
Updated: Aug 6, 2026
12:45
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
Anti-inflammatory effect of cardiac resynchronization therapy
Knut T Lappegård1, Hanne Bjørnstad
1Department of Medicine, Nordland Hospital, Bodø, Norway. knut.lappegard@nlsh.no
Pacing and Clinical Electrophysiology : PACE
|August 4, 2006
Summary
Cardiac resynchronization therapy (CRT) may reduce immune activation in patients with congestive heart failure (CHF). This study found reduced inflammatory markers after CRT, suggesting a potential anti-inflammatory effect of this heart failure treatment.
Area of Science:
- Cardiology
- Immunology
- Heart Failure Research
Background:
- Congestive heart failure (CHF) is linked to ongoing immune system activation.
- Conventional medical therapies offer limited anti-inflammatory benefits for CHF patients.
- The impact of cardiac resynchronization therapy (CRT) on immune activation in CHF is unknown.
Purpose of the Study:
- To investigate whether CRT influences immune activation markers in patients with CHF.
- To assess changes in inflammatory markers before and after CRT implantation.
Main Methods:
- Eight patients with CHF scheduled for CRT were enrolled.
- Immune activation markers were measured before and 6 months after CRT treatment.
- Clinical parameters including NYHA-class and LVEF were also assessed.
Main Results:
- Patients showed improved NYHA-class and LVEF, with reduced N-terminal pro brain natriuretic peptide (BNP) after CRT.
- Significant reductions were observed in plasma levels of monocyte chemoattractant protein 1 (MCP-1), interleukin 8 (IL-8), and interleukin 6 (IL-6).
- No significant changes were noted in IL-1beta, TNF-alpha, IL-10, or complement activation products.
Conclusions:
- CRT appears to reduce peripheral markers of immune activation in CHF patients.
- These findings suggest a potential anti-inflammatory role for CRT in heart failure management.
- Larger studies are needed to confirm these preliminary results.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:23Rheumatic Heart Disease I: Introduction
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
01:21Myocarditis I: Introduction
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...